CYTK vs. JAZZ, ELAN, VKTX, ITCI, IONS, CERE, APLS, BPMC, ASND, and LEGN
Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Jazz Pharmaceuticals (JAZZ), Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Ionis Pharmaceuticals (IONS), Cerevel Therapeutics (CERE), Apellis Pharmaceuticals (APLS), Blueprint Medicines (BPMC), Ascendis Pharma A/S (ASND), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical preparations" industry.
Jazz Pharmaceuticals (NASDAQ:JAZZ) and Cytokinetics (NASDAQ:CYTK) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, community ranking, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.
Jazz Pharmaceuticals has a net margin of 10.82% compared to Jazz Pharmaceuticals' net margin of -6,988.63%. Cytokinetics' return on equity of 31.27% beat Jazz Pharmaceuticals' return on equity.
Jazz Pharmaceuticals has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Jazz Pharmaceuticals received 323 more outperform votes than Cytokinetics when rated by MarketBeat users. Likewise, 80.49% of users gave Jazz Pharmaceuticals an outperform vote while only 79.14% of users gave Cytokinetics an outperform vote.
Jazz Pharmaceuticals has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
In the previous week, Cytokinetics had 5 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 14 mentions for Cytokinetics and 9 mentions for Jazz Pharmaceuticals. Cytokinetics' average media sentiment score of 0.65 beat Jazz Pharmaceuticals' score of 0.36 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.
89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 3.4% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Jazz Pharmaceuticals presently has a consensus target price of $195.08, indicating a potential upside of 76.15%. Cytokinetics has a consensus target price of $79.33, indicating a potential upside of 29.38%. Given Cytokinetics' higher probable upside, equities analysts clearly believe Jazz Pharmaceuticals is more favorable than Cytokinetics.
Summary
Jazz Pharmaceuticals beats Cytokinetics on 13 of the 18 factors compared between the two stocks.
Get Cytokinetics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytokinetics Competitors List
Related Companies and Tools
